Company News
Atossa Therapeutics Jumps 10% on FDA Designation
Atossa Therapeutics shares surged 10.3% after FDA granted Rare Pediatric Disease designation to (Z)-endoxifen for McCune-Albright Syndrome.
The RPD status makes Atossa eligible for a Priority Review V
